在晚期卵巢癌新辅助化疗中添加贝瓦齐祖马布的好处和危害:一项元分析
Zeyi Zhao1, Lei Cheng2, Xin Tong3
1Department of Oncology, Jining NO.1 People's Hospital, Jining, China.
Future oncology (London, England)
|August 22, 2025
概括
在晚期卵巢癌的新辅助化疗中添加贝瓦齐祖马布可以改善细胞减小率,但会增加胃肠道穿孔的风险. 需要进一步研究以平衡卵巢癌患者的疗效和毒性.
科学领域:
- 癌症学
- 妇科瘤学
- 临床药理学
背景情况:
- 晚期卵巢癌 (AOC) 存在重大治疗挑战.
- 新辅助化疗 (NACT) 是AOC的一种标准方法.
- 作为一种抗血管性药物,贝瓦西祖马布正在进行研究,以提高NACT的疗效.
研究的目的:
- 在AOC中评估bevacizumab与NACT结合的疗效和毒性.
- 为了比较bevacizumab-NACT和标准NACT之间的结果.
主要方法:
- 随机临床试验,队列研究和病例系列的系统审查和元分析.
- 搜索了PubMed,EMBASE,Scopus和科学网络的数据库.
- 包括2010年11月至2024年12月间发表的研究.
主要成果:
- 贝瓦西祖马布-NACT显著增加了最佳细胞减少率 (RR:1.17,P=0.02).
- 在完整的细胞减少,手术实施,伤口并发症,血栓形成或感染方面没有发现显著差异.
- 在贝瓦齐祖马布-NACT组中,发现胃肠穿孔的风险增加 (RR: 6. 97, P=0. 02).
结论:
- 在AOC中添加贝瓦西祖马布可以提高细胞减小的最佳可行性.
- 联合治疗与胃肠道穿孔的风险增加有关.
- 在使用贝瓦西祖马布-NACT时,仔细选择和监测患者至关重要.
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
321
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
321
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
440
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
440
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
259


